This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Ascentage Pharma Group Corp Limited, Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma (Suzhou) Co., Ltd.. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 29 
1 out of 31 
1 out of 10 
Years Active: 2025-2026
Title: Xianchan Zha: Innovator in Cancer Treatment
Introduction
Xianchan Zha is a notable inventor based in Suzhou, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cancer treatment.
Latest Patents
Xianchan Zha holds a patent for "Macrocyclic fused pyrazoles as Mcl-1 inhibitors." This patent includes compounds represented by Formula IA, along with their pharmaceutically acceptable salts and solvates. These compounds are designed to treat conditions responsive to Mcl-1 inhibition, such as cancer.
Career Highlights
Throughout his career, Xianchan Zha has worked with Ascentage Pharma (Suzhou) Co., Ltd. and the University of Michigan. His work has focused on innovative solutions in the pharmaceutical industry, particularly in cancer research.
Collaborations
Xianchan Zha has collaborated with notable colleagues, including Guozhi Tang and Dongbo Li. Their combined expertise has contributed to advancements in cancer treatment methodologies.
Conclusion
Xianchan Zha's work in developing Mcl-1 inhibitors showcases his commitment to advancing cancer treatment. His innovative approach and collaborations highlight the importance of research in the pharmaceutical field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile